Mesenteric Ischemia Markers Study
Sponsor: Belarusian State Medical University • ClinicalTrials.gov ID: NCT07460700
Recruiting for Similar Conditions?
Sponsors are looking for patients like you. See if you qualify for compensated research studies.
Check Eligibility →Description
Vascular bowel disease remains a socially significant and potentially fatal condition (if it develops into AMI), primarily due to delayed diagnosis. Blood biomarkers are theoretically ideal for early risk stratification (like troponins in myocardial infarction). However, the existing evidence base is characterized by low quality and high heterogeneity, which hinders their use in clinical practice. Therefore, there is an urgent and unmet clinical need for high-quality, methodologically rigorous research to validate biomarkers in MI. A current study (MESMARK) is to be undertaken to identify combinations of biomarkers that can reliably identify mesenteric ischemia (MI) and distinguish between non-transmural and transmural clinical relevant ischemia.
Interventions
-
Blood samples
(Diagnostic test)
Blood samples as diagnostic tests are the only intervention in the trial
Eligibility criteria
Conditions
Locations
- Belarusian State Medical University — Minsk, Belarus
Partner with Nurenyx
Showcase your study to thousands of motivated patients matching your criteria.
Learn MoreOfficial Source
Data sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
View Official Record